{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:12:17Z","timestamp":1747195937984,"version":"3.40.5"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>This study was to compare the efficacy and safety of combined glycoprotein IIb\/IIIa inhibitor (GPI) and ticagrelor versus ticagrelor in patients with acute coronary syndrome (ACS). An observational study was conducted using the Improving Care for Cardiovascular Disease in China-ACS project. Totally, 13,264 patients with ACS and received combination therapy or ticagrelor therapy were analyzed. The primary outcome was the composite of major cardiovascular events (MACE: all-cause mortality, myocardial infarction [MI], stent thrombosis, cardiogenic shock, and ischemic stroke), and secondary outcomes included all-cause mortality, MI, stent thrombosis, cardiogenic shock, and ischemic stroke. The multivariable adjusted analysis indicated that combination therapy was associated with an increased risk of major cardiovascular events (MACE) (<jats:italic>P<\/jats:italic> = 0.001), any bleeding (<jats:italic>P<\/jats:italic>&lt;0.001), and major bleeding (<jats:italic>P<\/jats:italic> = 0.005). Moreover, the multivariable adjusted for propensity score-matched (PSM) analysis suggested that combination therapy produced additional risk of MACE (<jats:italic>P<\/jats:italic> = 0.014), any bleeding (<jats:italic>P<\/jats:italic>&lt;0.001), and major bleeding (<jats:italic>P<\/jats:italic> = 0.005). Moreover, PSM analysis suggested that combination therapy was associated with greater risk of stent thrombosis (<jats:italic>P<\/jats:italic> = 0.012) and intracranial bleeding (<jats:italic>P<\/jats:italic> = 0.020). Combined GPI and ticagrelor therapies did not have any beneficial effects on MACE, stent thrombosis, intracranial bleeding, any bleeding, or major bleeding.<\/jats:p>","DOI":"10.1371\/journal.pone.0246166","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T20:25:06Z","timestamp":1612297506000},"page":"e0246166","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combined glycoprotein IIb\/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome"],"prefix":"10.1371","volume":"16","author":[{"given":"Zhi-Jiang","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-7036","authenticated-orcid":true,"given":"Shuan-Li","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Hui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"pone.0246166.ref001","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1161\/01.CIR.103.21.2572","article-title":"Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study","volume":"103","author":"SR Steinhubl","year":"2001","journal-title":"Circulation"},{"key":"pone.0246166.ref002","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"S Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"pone.0246166.ref003","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0246166.ref004","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jacc.2015.11.044","article-title":"Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI","volume":"67","author":"DJ Angiolillo","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"pone.0246166.ref005","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cjca.2019.05.003","article-title":"Routine Glycoprotein IIb\/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-analysis","volume":"35","author":"A Karathanos","year":"2019","journal-title":"Can J Cardiol"},{"key":"pone.0246166.ref006","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"E Investigators","year":"1994","journal-title":"N Engl J Med"},{"key":"pone.0246166.ref007","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable S, Symptoms Study I","year":"1998","journal-title":"N Engl J Med"},{"key":"pone.0246166.ref008","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"E Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"pone.0246166.ref009","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","article-title":"Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial","volume":"295","author":"A Kastrati","year":"2006","journal-title":"JAMA"},{"key":"pone.0246166.ref010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCULATIONAHA.110.958041","article-title":"Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb\/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial","volume":"123","author":"TY Wang","year":"2011","journal-title":"Circulation"},{"key":"pone.0246166.ref011","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(07)60450-4","article-title":"Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial","volume":"369","author":"GW Stone","year":"2007","journal-title":"Lancet"},{"key":"pone.0246166.ref012","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"EA Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"pone.0246166.ref013","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ahj.2016.06.005","article-title":"Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort to prompt quality enhancement for acute coronary syndrome","volume":"179","author":"Y Hao","year":"2016","journal-title":"Am Heart J"},{"key":"pone.0246166.ref014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12933-018-0793-x","article-title":"Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project","volume":"17","author":"M Zhou","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"pone.0246166.ref015","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjcard.2010.12.009","article-title":"In-hospital major bleeding during ST-elevation and non-ST-elevation myocardial infarction care: derivation and validation of a model from the ACTION Registry(R)-GWTG","volume":"107","author":"R Mathews","year":"2011","journal-title":"Am J Cardiol"},{"key":"pone.0246166.ref016","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008100","article-title":"In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project","volume":"7","author":"G Zhao","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"pone.0246166.ref017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/09537100500163226","article-title":"Glycoprotein IIb\/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses","volume":"16","author":"HM Judge","year":"2005","journal-title":"Platelets"},{"key":"pone.0246166.ref018","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.jacc.2005.07.041","article-title":"Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study","volume":"46","author":"PA Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"pone.0246166.ref019","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.2010.181","article-title":"Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation","volume":"303","author":"NJ Breet","year":"2010","journal-title":"JAMA"},{"key":"pone.0246166.ref020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","article-title":"Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study","volume":"382","author":"GW Stone","year":"2013","journal-title":"Lancet"},{"key":"pone.0246166.ref021","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jcin.2009.10.024","article-title":"High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention","volume":"3","author":"F Mangiacapra","year":"2010","journal-title":"JACC Cardiovasc Interv"},{"key":"pone.0246166.ref022","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jcmg.2015.08.019","article-title":"Relationship Between Platelet Reactivity and Culprit Lesion Morphology: An Assessment From the ADAPT-DES Intravascular Ultrasound Substudy","volume":"9","author":"KH Yun","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"pone.0246166.ref023","first-page":"3238","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"36","author":"F Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"pone.0246166.ref024","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1532-5415.2010.03305.x","article-title":"Exclusion of older adults and women from recent trials of acute coronary syndromes","volume":"59","author":"KS Dodd","year":"2011","journal-title":"J Am Geriatr Soc"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T20:25:21Z","timestamp":1612297521000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246166"}},"subtitle":[],"editor":[{"given":"Andreas","family":"Zirlik","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246166","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,2,2]]}}}